Jing Zhao

TL;DR: DC-CIK combined with chemotherapy administration resulted in numerically superior PFS and OS compared with monotherapy in advanced NSCLC.

TL;DR: Combining HT with ACT plus either CT or anti-PD-1 antibody was safe, generated clinical responses in previously treated advanced cancers, and promoted TCR repertoire diversity and favorable changes in serum IL-2, IL-4, TNF-α, and IFN-γ levels in clinical responders.

TL;DR: In this paper, the authors explored the impact of the human microbiota on other forms of immunotherapy, including immune checkpoint blockades, on the response of malignancies to treatment with immune checkpoint blockade.

TL;DR: Patients with EGFR gene mutation may acquire a longer median survival time after receiving targeted drug therapy, due to the drop of mutation abundance, while the therapy may have a minor effect in patients which their mutation abundances have slightly decreased compared to the statistics before the cession.

TL;DR: Identification of these cytokines would facilitate developing novel serum biomarkers for MBC, favoring multiplexed serum cytokine profiling a promising method in predicting the outcome of MBC patients.